Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT00095147. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase IIIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Comparative Study of Abatacept or Infliximab in Combination With Methotrexate in Controlling Disease Activity in Subjects With Rheumatoid Arthritis Having an Inadequate Clinical Response to Methotrexate
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this clinical research study is to learn if Abatacept or Infliximab in combination with Methotrexate demonstrate a greater reduction in disease activity over placebo.
Study identification
- NCT ID
- NCT00095147
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 431 participants
Conditions and interventions
Conditions
Interventions
- Abatacept (ABA) + Methotrexate (MTX), double-blind (DB) Drug
- Infliximab (INF) + MTX, DB Drug
- Placebo (PLA) + MTX, DB Drug
- PLA + MTX switched to ABA+ MTX, DB Drug
- ABA, open-label (OL) Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2005
- Primary completion
- Jun 30, 2009
- Completion
- Jun 30, 2009
- Last update posted
- Mar 23, 2015
2005 – 2009
United States locations
- U.S. sites
- 19
- U.S. states
- 13
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution | Huntsville | Alabama | — | — |
| Local Institution | Denver | Colorado | — | — |
| Local Institution | Boca Raton | Florida | — | — |
| Local Institution | Fort Lauderdale | Florida | — | — |
| Local Institution | Largo | Florida | — | — |
| Local Institution | Indianapolis | Indiana | — | — |
| Local Institution | New Orleans | Louisiana | — | — |
| Local Institution | Springfield | Massachusetts | — | — |
| Local Institution | Worcester | Massachusetts | — | — |
| Local Institution | Flowood | Mississippi | — | — |
| Local Institution | Syracuse | New York | — | — |
| Local Institution | Charlotte | North Carolina | — | — |
| Local Institution | Cincinnati | Ohio | — | — |
| Local Institution | Oklahoma City | Oklahoma | — | — |
| Local Institution | Tulsa | Oklahoma | — | — |
| Local Institution | Bethlehem | Pennsylvania | — | — |
| Local Institution | Willow Grove | Pennsylvania | — | — |
| Local Institution | Austin | Texas | — | — |
| Local Institution | Dallas | Texas | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 57 non-U.S. sites.
Recently updated Rheumatoid Arthritis trials
Other public records listing Rheumatoid Arthritis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07137598: A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) Recruiting
- NCT04817969: Persona Ti-Nidium Post-Market Clinical Follow-up Active, not recruiting
- NCT07620392: An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis Recruiting
- NCT05936970: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD Active, not recruiting
- NCT07704580: Phase 1b/2 Study of IV Sarilumab in Adult With RA Recruiting
- NCT07293871: Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00095147, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 23, 2015 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00095147 live on ClinicalTrials.gov.